Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Trump’s Proposed Budget Undermines His H.I.V. Plan, Experts Say

Strategies abound to end the AIDS epidemic, but expense — mostly for drugs costing up to $50,000 a year — is the inevitable obstacle.

Published
14 March 2019
From
The New York Times
Gilead's Descovy snared its PrEP data, but can it stand up to Truvada generics?

Gilead Sciences has the data it’ll need to start transitioning patients taking Truvada for PrEP over to Descovy, a drug with a longer patient life. But once Truvada generics hit, it might be a different story.

Published
14 March 2019
From
FiercePharma
Big Pharma Gave Money To Patient Advocacy Groups Opposing Medicare Changes

Dozens of patient advocacy groups, like the Bonnie J. Addario Lung Cancer Foundation and the National Coalition for Cancer Survivorship, recently appeared in national advertisements objecting to a Trump administration proposal that could limit drugs covered by Medicare providers. But a Kaiser Health News analysis found that about half of the groups representing patients have received funding from the pharmaceutical industry.

Published
05 March 2019
From
Kaiser Health News
Should the NIH Break HIV Prevention Drug Truvada's Patent?

Should a biotech giant holding a valuable patent be forced to give it up if doing so would serve the public good? That’s the mounting debate over Gilead Sciences’ hold on an HIV prevention treatment, which some say is too expensive and should be available to all.

Published
05 March 2019
From
Fortune
Hepatitis C Treatment Market to Exceed US$ 71.13 Bn by the end of 2024

The global hepatitis C treatment market was valued at US$ 23.9 Bn in 2015 and is estimated to be valued at US$ 26.6 Bn by 2016. The market is expected to reach a valuation of US$ 71.13 Bn by the end of 2024, reflecting a cumulative annual growth rate of 13.1% over the forecast period.

Published
04 March 2019
From
Honest Businessman
A new way to pay for innovative drugs, provide universal access and not break the bank

Louisiana, which has a severe hepatitis C problem, is on the cusp of proving to other states that drug companies can make the money they need, while every Medicaid recipient who needs a cure gets one. The state is now on a path to secure immediate treatment for all infected prisoners and people on Medicaid by buying a license from a drug company. It is a concept that can be applied to other ground breaking remedies.

Published
28 February 2019
From
The Conversation
Analysis: How a cutting edge medicine made it to South Africa’s new ARV tender

South Africa’s recently awarded antiretroviral (ARV) tender, worth around R14-billion over three years, heralds the introduction of a much-anticipated new medicine called dolutegravir into the public healthcare system from July 2019. For a cutting-edge HIV drug to reach the public sector so quickly, and at such a low price, is unprecedented.

Published
27 February 2019
From
Spotlight
The Good Law Project threatens Judicial Review of Serious Shortage Protocols

The Good Law Project has today threatened to issue judicial review proceedings on Tuesday 26 February unless Government cancels powers to allow pharmacists to alter prescriptions for people with serious medical conditions in the event of medicines shortages. The powers – called “Serious Shortage Protocols” (SSPs) – give pharmacists the right to supply a different quantity or pharmaceutical quality of medicine in the event of the country experiencing a serious shortage of prescription-only medicines after 29 March 2019. These new powers took force on 9 February, and have been criticised for being rushed out without proper consultation with patient and clinical groups.

Published
24 February 2019
From
Good Law Project
US: The struggle to maintain access to lifesaving HIV meds

President Trump actually proposed a plan in his State of the Union address to end the HIV epidemic in America by 2030. This lofty goal would be thwarted, however, by proposed changes to Medicare Part D that jeopardize the advancements we’ve made in the fight against HIV.

Published
24 February 2019
From
Washington Blade
The Trump Administration's Drug Pricing Proposals for People With HIV, Explained

Every once in a while, we like to try to explain wonky policy proposals that haven't happened yet but that could be of significance for HIV-positive folks if they do.

Published
20 February 2019
From
The Body
← First12345...107Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.